Group 1 - InterGlobe Aviation will be added to the BSE Sensex index, replacing Tata Motors Passenger Vehicles, effective from December 22 [4][3] - The inclusion of InterGlobe Aviation indicates its growing market presence and reflects a significant shift in sector representation within the benchmark, moving from automobiles to aviation [4][3] - The reshuffle will also involve changes in other indices, with IDFC First Bank replacing Adani Green Energy in the BSE 100 index and Max Healthcare Institute replacing IndusInd Bank in the BSE Sensex 50 [4][3] Group 2 - Index changes typically lead to portfolio realignment among index-tracking funds and exchange-traded funds, resulting in mechanical buying and selling as funds adjust their holdings [3][4] - The announcement of these changes highlights the evolving dynamics within India's equity markets and the shifts in category leadership over time [4]

Group 1 - UnitedHealth Group Incorporated (NYSE:UNH) is receiving positive attention from analysts, with a consensus 1-year median price target of $410, indicating a potential upside of 28% [1] - Wells Fargo analyst Stephen Baxter reaffirmed a Buy rating on UnitedHealth with a price target of $400, while a Barclays analyst maintained a Buy rating with a price target of $386 [1] - The company announced the addition of Scott Gottlieb, former FDA commissioner, to its board, effective immediately [2] Group 2 - Scott Gottlieb is recognized for his public health advocacy, particularly in reducing flavored e-cigarette use among youths, and has experience in enhancing competition through expedited approvals [3] - UnitedHealth operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, and is committed to improving the healthcare system since its founding in 1974 [4]

Core Viewpoint - The upcoming reshuffle in the BSE Sensex on December 22 signifies a shift in India's equity benchmark, with InterGlobe Aviation replacing Tata Motors Passenger Vehicles, reflecting changes in market leadership and corporate restructuring [5]. Group 1: Index Changes - InterGlobe Aviation will replace Tata Motors Passenger Vehicles in the Sensex index, marking a significant transition in the index composition [5]. - IDFC First Bank Ltd will be included in the BSE 100 index, replacing Adani Green Energy Ltd [5]. - Max Healthcare Institute Ltd will be added to the BSE Sensex 50, while IndusInd Bank Ltd will be removed [5]. - In the BSE Sensex Next 50 index, IndusInd Bank and IDFC First Bank will replace Max Healthcare Institute Ltd and Adani Green Energy [5]. Group 2: Market Implications - The inclusion of InterGlobe Aviation indicates its growing market prominence, while Tata Motors PV's exit is attributed to its recent demerger from Tata Motors [5]. - The rebalancing of the indices ensures they remain representative of India's evolving market landscape [4][5]. - The changes will necessitate mandatory reallocation by index-tracking funds and exchange-traded funds, leading to mechanical buying and selling as portfolios adjust to the new index composition [4][5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 2, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and a dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant reduction in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and operations were materially misleading and lacked a reasonable basis [5].

Core Points - InterGlobe Aviation, operator of IndiGo, will be included in the BSE Sensex index starting December 22 [3][4] - Tata Motors Passenger Vehicles Ltd will be removed from the BSE Sensex index as part of the reconstitution [3][4] - IDFC First Bank Ltd will be added to the BSE 100 index, replacing Adani Green Energy Ltd [3][4] - Max Healthcare Institute Ltd will be included in the BSE Sensex 50 index, while IndusInd Bank Ltd will be removed [3][4] - In the BSE Sensex Next 50 index, IndusInd Bank and IDFC First Bank will replace Max Healthcare Institute and Adani Green Energy [3][4]

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][3]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in revenue for Q3 2025 after conducting evaluations of historical collection trends [4]. - The company also increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [4]. - Following these disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [4]. Legal Context - Bleichmar Fonti & Auld LLP is leading the investigation and encourages affected investors to seek additional information and potential legal options [2][5]. - The law firm operates on a contingency fee basis, meaning shareholders are not responsible for court costs or litigation expenses [5]. Company Overview - Ardent Health, Inc. provides healthcare services in mid-sized urban communities across the U.S., operating a network of hospitals, ambulatory facilities, and physician practices [3].

Financial Data and Key Metrics Changes - The company reported a 5% decline in total adjusted EBITDA, primarily due to weaker performance in Mexico [6][9] - Adjusted net income for the quarter was PEN 58 million, with a 1% increase in FX-neutral consolidated revenue driven by Peru and Colombia [9][18] - Capacity utilization decreased by 3 percentage points to 64%, with a 1.5 percentage point increase in Peru offset by declines in Colombia and Mexico [9][10] Business Line Data and Key Metrics Changes - Peru's top line and EBITDA grew by 9% and 15% respectively, driven by an improving healthcare pricing mix and strong insurance MLR [7][18] - Colombia's revenue increased by 5%, supported by risk-sharing models, with adjusted EBITDA rising by 18% [19][18] - Mexico experienced a 12% decline in revenue, although surgery volumes and oncology services showed growth [11][12] Market Data and Key Metrics Changes - Peru accounted for over half of the company's revenues, with a solid growth trajectory [21] - Colombia's revenue share from Nueva EPS decreased from 20% to 13%, indicating successful diversification of payers [19][45] - Mexico's revenue decline was attributed to a slow recovery in volumes and non-operating impacts from system migrations [21][9] Company Strategy and Development Direction - The company aims to enhance its growth in Mexico through a partnership with Sojitz, focusing on co-investment opportunities [32][39] - Auna is committed to maintaining a leverage ratio below three times net debt to EBITDA while pursuing growth initiatives [28][32] - The Trecca project in Peru is expected to generate significant revenue, with a focus on expanding services to state beneficiaries [53][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for a recovery in Mexico in 2026, despite current challenges [8][32] - The company remains focused on improving operational efficiency and expanding its market presence in Peru and Colombia [30][31] - Management highlighted the importance of attracting and retaining healthcare talent in Mexico to drive growth [13][15] Other Important Information - The company successfully refinanced $765 million in debt, improving its debt profile and financial flexibility [27][28] - Auna's cash position at the end of the quarter was PEN 226 million, reflecting a 4.2% decrease from the beginning of the year [26] Q&A Session Summary Question: Could you explain the rationale for expanding in Mexico and how it aligns with your deleveraging goals? - Management emphasized that the partnership with Sojitz will help accelerate growth in Mexico while maintaining leverage targets [39][40] Question: Do you think a change in Colombia's leadership could ease pressures on EPSs? - Management indicated that while political changes may not yield immediate results, there are signs of stabilization in the Colombian healthcare sector [40][41] Question: What key KPIs should be tracked to confirm a recovery in 2026? - Management suggested monitoring occupancy, payer mix, and surgical productivity as indicators of recovery [61] Question: What is the nature of the $500 million investment plan in Mexico? - Management confirmed that the investment plan is related to the MOU with Sojitz and aims to drive significant top-line growth [72] Question: How is Auna managing insurance risk at a group level? - Management explained that risk is managed through continuous repricing and cost containment strategies [75][78] Question: Have the preferred payer network and bundled packages for corporates been launched? - Management confirmed that the preferred payer network has been launched and is continuously evolving [79][80]

Financial Data and Key Metrics Changes - The company reported weaker financial results for Q3 2025, with a 5% decline in total adjusted EBITDA primarily due to performance in Mexico [6][9] - Adjusted net income was PEN 58 million for the quarter, with FX-neutral consolidated revenue increasing by 1% [9][24] - Capacity utilization decreased by 3 percentage points to 64%, with a 1.5 percentage point increase in Peru offset by declines in Colombia and Mexico [9][10] Business Line Data and Key Metrics Changes - Peru's top line and EBITDA grew by 9% and 15% respectively, driven by an improving healthcare pricing mix and strong insurance MLR [7][18] - Colombia's revenue increased by 5%, supported by risk-sharing models, while adjusted EBITDA grew by 18% [19][21] - Mexico experienced a 12% revenue decline, although surgery volumes and oncology services showed growth [9][11] Market Data and Key Metrics Changes - Peru accounted for over half of the company's revenues, with a solid growth trajectory [21] - Colombia's revenue share from Nueva EPS decreased from 20% to 13%, indicating successful diversification [19][45] - Mexico's revenue decline was attributed to a slow recovery in volumes and non-operating impacts from system migrations [21][24] Company Strategy and Development Direction - The company aims to capture long-term growth opportunities in Mexico, anticipating a full recovery in 2026 [8][32] - Auna is focusing on enhancing its oncology capabilities and expanding its service offerings in Mexico [16][14] - The partnership with Sojitz is expected to accelerate growth in Mexico while maintaining leverage targets [39][72] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in Mexico but expressed optimism about future growth and recovery [6][32] - The company remains committed to improving its leverage ratio and enhancing shareholder value [27][62] - Management highlighted the resilience of its integrated model and the potential for growth in Peru and Colombia despite external challenges [30][41] Other Important Information - Auna successfully completed a $765 million debt refinancing, improving its debt profile and financial flexibility [27][28] - The company is implementing a new comprehensive IT system to enhance operational efficiency and data management [17][12] Q&A Session Summary Question: Could you explain the rationale for expanding in Mexico and how it aligns with your goal to deleverage Auna? - Management emphasized that Auna is a growth story and sees significant opportunities in Mexico, with the partnership with Sojitz facilitating this growth while maintaining leverage targets [39][40] Question: Do you think a potential change in Colombia's leadership could ease pressures on EPSs? - Management indicated that while political changes may not have immediate effects, there are signs of stabilization in the Colombian healthcare sector [40][45] Question: What key KPIs should be tracked to confirm a tangible recovery in 2026? - Management suggested monitoring occupancy, payer mix, and surgical productivity as key indicators of recovery [61] Question: Could you provide more details around the partnership with Sojitz and the TRECA project? - Management confirmed that the TRECA project is a significant public-private partnership that will enhance Auna's service capabilities in Peru [52][53] Question: How do you plan to increase out-of-pocket sales mix in Mexico? - Management outlined initiatives to aggressively capture out-of-pocket patients through packaged services and improved pricing strategies [80][81]

Financial Data and Key Metrics Changes - The company reported weaker financial results for Q3 2025, with a 5% decline in total adjusted EBITDA primarily due to performance in Mexico [6][9] - Adjusted net income was PEN 58 million for the quarter, with FX-neutral consolidated revenue increasing by 1% [9][22] - Capacity utilization decreased by 3 percentage points to 64%, with a 1.5 percentage point increase in Peru offset by declines in Colombia and Mexico [9][10] Business Line Data and Key Metrics Changes - Peru's revenue grew by 9% and adjusted EBITDA increased by 15%, driven by improved healthcare pricing mix and strong insurance MLR [9][19] - Colombia's revenue grew by 5%, with adjusted EBITDA increasing by 18%, attributed to risk-sharing models and higher average tickets for surgery [20][21] - Mexico experienced a 12% revenue decline, although surgery volumes and oncology services increased [11][12] Market Data and Key Metrics Changes - Peru accounted for over half of the company's revenues, continuing to be a strong growth driver [21] - Colombia's share of revenues from major government payers decreased from 20% to 13%, indicating successful diversification efforts [20][21] - Mexico's revenue decline was influenced by a slower market and operational challenges, including the implementation of new IT systems [12][21] Company Strategy and Development Direction - The company is focused on capturing long-term growth opportunities in Mexico, anticipating a full recovery in 2026 [8][30] - Auna is rolling out new service offerings and enhancing collaboration with physicians to penetrate profitable market segments [14][15] - The partnership with Sojitz Corporation aims to accelerate growth in Mexico while maintaining a disciplined deleveraging path [31][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Mexico's recovery, highlighting stable hospital operations and increased service volumes [6][8] - The company remains committed to improving its leverage ratio to below three times net debt to EBITDA in the medium term [26][27] - Management acknowledged the challenges in Colombia but emphasized the strength of Auna's positioning and growth potential [36][38] Other Important Information - Auna successfully refinanced $765 million in debt, improving its debt profile and extending maturities [26][27] - The company is implementing a comprehensive IT system to enhance operational efficiency and data management [18] Q&A Session Summary Question: Future strategy in Mexico and the rationale for expanding - Management clarified that the partnership with Sojitz is aimed at accelerating growth in Mexico while maintaining leverage targets [34][35] Question: Potential changes in Colombia's leadership and their impact - Management indicated that while political changes may not yield immediate improvements, there are signs of stabilization in the Colombian healthcare sector [36][38] Question: Key KPIs to track for recovery in 2026 - Management highlighted occupancy, payer mix, and surgical productivity as critical KPIs to monitor for tangible recovery [44] Question: Recent share price weakness and institutional investor activity - Management noted that the current share price does not reflect the company's fundamentals and is evaluating options to enhance shareholder value [45] Question: Return on investment timeline for Mexico performance - Management expects 2026 to be a growth year for Mexico, despite setbacks in 2025 [47] Question: Expansion plans in Peru and Mexico - Management confirmed plans to increase capacity in both countries, focusing on high-complexity services [48] Question: Details on the partnership with Sojitz and investment plans - Management confirmed that the $500 million investment plan is related to the MoU with Sojitz, aimed at significant top-line growth [49][50]

Q3 2025 This presentation has been prepared by Auna S.A. ("Auna" or the "Company") solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other party without the Company's prior written consent is prohibited. This presentation contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These s ...